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Aim. Rictor is a component of the protein complex mTORC2 that is activated by growth factors and regulates 
cell growth, survival and migration. Here, we describe the development of the Rictor specific monoclonal 
antibody and characterize its suitability for various immunological assays. Methods. Hybridoma technology 
has been used for the monoclonal antibody production. Immunization was carried out with the recombinant 
N-terminal fragment of human Rictor expressed in E. coli as a GST-tagged fusion protein. Results. Specific 
monoclonal antibody (mAb) against Rictor has been developed. Conclusions. The generated mAb specifi-
cally recognizes the recombinant and endogenous Rictor and is suitable for Western blotting, immunoprecipi-
tation, and immunofluorescence assays of mammalian cells. This mAb will be a useful tool for the investiga-
tions of a  physiological role of Rictor as well as the function of the mTORC2 in general.
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Introduction
The mammalian target of rapamycin (mTOR) sig-
naling pathway is a central regulator of cell metabo-
lism, growth, proliferation and survival and is de-
regulated in human diseases such as cancer, neuro-
degeneration, metabolic disorders and ageing [1]. 
The mTOR protein is a serine-threonine kinase and 
nucleates two distinct multi-protein complexes, 
mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2), which regulate diverse cellular pro-
cesses.
mTORC1 consists of the catalytic subunit – 
mTOR, the regulatory-associated protein of mTOR 
(Raptor), mLST8 or mammalian lethal with Sec13 
protein 8 (also known as GβL), PRAS40 or proline 
rich Akt substrate 40 kDa, Deptor or DEP-domain-
containing mTOR-interacting protein, and the Tti1/
Tel2 complex [1]. The function of mTORC1 is tight-
ly regulated by PI3-K/Akt and is sensitive to ra-
pamycin [2]. Among the multiple functions of 
mTORC1, the best-characterized function is regula-
tion of translation. It is performed via two down-
stream mediators, the eukaryotic initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and the p70 ri-
bosomal S6 kinase 1 (p70S6K1, S6K1). The latter 
demonstrates an aberrant expression in the various 
diseases or pathological states [3, 4].
mTORC2 contains mTOR, rapamycin-insensitive 
companion of mTOR (Rictor), mammalian stress-
activated MAP-kinase interacting protein (mSIN1), 
and protein observed with Rictor 1 and 2 (Protor-1/2), 
mLST8, Deptor and the Tti/Tel2 complex [5–8]. The 
studies that define the mTORC2 cellular functions 
and signaling have lagged behind. mTORC2 is sen-
sitive to the growth factors, not nutrients, and, in 
contrast to mTORC1, is associated with rapamycin-
insensitivity [5]. mTORC2 is also thought to modu-
late the growth factor signaling by phosphorylating 
the C-terminal hydrophobic motif of some AGC ki-
380
O. M. Malanchuk
nases such as Akt [9, 10], SGK [11], and PKC alpha 
[12, 13], and participates in the actin cytoskeleton 
rearrangements and cell survival but a detailed 
mechanism remains to be addressed. 
So, taking into account a key role of the mTOR 
signalling cascade in the regulation of major multi-
ple cellular functions, a more detailed understanding 
of its functioning and regulation will lead to new 
therapies for many human diseases. Furthermore, 
little is known about the precise role of unique com-
ponents of mTORC1 (Raptor) and mTORC2 (Rictor) 
in cell signalling outside the complexes. 
Therefore, the use of monoclonal antibodies to the 
key components of the complexes to distinguish 
them from each other could be a useful tool for the 
study of the above questions, particularly in the con-
text of the localization and colocalization of both 
complexes in cells at different physiological and 
pathophysiological conditions. The lack of commer-
cially available highly specific Rictor monoclonal 
antibodies (mAb), which could be used in all me-
thods (Western-blot, immunoprecipitation and im-
munofluorescence assays), prompted us to develop 
this reagent. The recombinant GST-tagged N-ter-
minal fragment of thec Rictor protein (GST-NtRictor) 
was used for the mice immunization and hybridoma 
screening procedure. Here, we report the develop-
ment of Rictor mAb that efficiently recognizes re-
combinant and endogenous Rictor in all immunoas-
says. 
Materials and Methods
Purification of GST-NtRictor fusion protein
The bacterial expression system has been used 
for production of human N-terminal Rictor frag-
ment (1–100 aa) – GST-NtRictor fusion protein. 
Generated plasmid pET42a/NtRictor was trans-
formed into E.coli Rosetta(DE3)pLysS and the ex-
pression of GST-NtRictor fused protein was induced 
with 1mM isopropyl-b-D(2)-thiogalactopyranoside 
(IPTG) for 3 h at + 37 °C. Affinity purification of 
GST- NtRictor was carried out under native condi-
tions using Glutathione-Sepharose (Amersham, UK) 
as recommended by manufacturers. The quality of 
the purified recombinant protein (estimated molecu-
lar weight is about 46 kDa) was tested by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE).
Immunization
Purified GST-NtRictor (15 μg) in emulsified 
Freund’s complete adjuvant (Sigma Chemical, St. 
Louis, MO) was injected intraperitoneally (i.p.) in 
8-week-old female BALB/c mice every two weeks. 
When the titer of anti-Rictor antibody in the serum 
of immunized mouse reached 10-5, the hybridomas 
production was performed according to a standard 
protocol [14]. Three days before fusion, intraperito-
neal immunization with 15 μg of GST-NtRictor was 
carried out.
Cell fusion
Briefly, generation of mAb has been performed as 
described earlier [15]. Hybridomas were produced by 
fusing splenocytes of an immunized BALB/c mouse 
with SP2/0 myeloma cells using PEG (MW2000, 
Merck, Germany) in 1:10 ratio. Cells were grown in 
RPMI-1640 (Biochrom AG, Berlin, Germany) sup-
plemented with 20 % FBS (v/v), 1x hypoxanthine-
aminopterin-thymidine (HAT, Sigma). After 7 days, 
supernatants of growing hybridomas were screened 
with ELISA using purified GST-NtRictor. GST pro-
tein served as negative control. Positive for GST-
NtRictor but not GST protein clones were selected 
and subcloned by limited serial dilution [14]. 
Supernatants of the growing hybridomas were used 
for further studies.
ELISA assay
Polystyrene 96-well plates were loaded with 
100μl of GST-NtRictor (0.3 μg/well) or GST (0.3 
μg/well) for 2 h at 37 °C. The plates were washed 
three times with PBS containing 0.1 % Tween-20 
(Sigma, USA). For blocking non-specific binding 
the plates were incubated with 2 % bovine serum 
albumin (BSA) in PBS (pH 7.4) overnight at 4 °C 
(200 μl/well). Subsequently, the plates were loaded 
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with 100 μl/well aliquots of hybridoma supernatant 
and incubated for 1 h at 37 °C, serum from immu-
nized mouse was used as positive control. After 
three times washing, 100 μl of horseradish peroxi-
dase (HRP)-conjugated goat anti-mouse IgG anti-
bodies (1:5000 v/v, Promega, USA) were added to 
each well following the incubation at 37 °C for 1 h. 
Plates were washed three times and substrate solu-
tion (0.02 % H2O2, 0.5 mg/ml 2.2’-azino-bis(3-eth-
ylbenzothiazoline-6-sulfonic acid) sodium salt 
(Sigma, USA) in 0.1 M citrate-phosphate buffer 
(pH 5.8) was added to each well. After 15 min incu-
bation at 37 °C, the absorbance of each well was 
determined at 450–490 nm in ELISA reader.
Positive clones selection by Western  
blot analysis
Bacterially expressed GST-NtRictor recombinant 
protein was boiled in SDS gel-loading buffer (5X), 
resolved by 10 % SDS/PAGE and electrotransferred 
to Immobilon-P membrane (Millipore, USA). The 
membrane was blocked by 0.5 % gelatin in PBS for 
1 h at room temperature (RT), washed with PBS 
containing 0.1 % Tween 20 and divided into strips. 
Strips were incubated with either PBS (negative 
control), the polyclonal serum collected from GST-
NtRictor immunized mouse (1:1000) (positive con-
trol), hybridoma supernatants from clones, or cell 
culture media alone (negative control) for 4 h at RT. 
After three times washing, HRP-conjugated goat 
anti-mouse lgG (Promega, USA) was added to the 
strips and incubated for 1 h at RT. Strips were 
washed three times, and developed by ECL Western 
blotting reagent (Amersham, Sweden). 
Purification of mAb
For monoclonal antibody ascitic fluid production, 
BALB/c mice were injected with 0.5 ml of Pristane 
and 10 days later inoculated with 5∙106 of hybridoma 
cells [14]. The ascitic fluid was collected after 12 
days. The fraction of immunoglobulins was precipi-
tated from ascitic fluid with 50 % ammonium sul-
fate, dialyzed overnight against phosphate-buffered 
saline (PBS) pH 7.4 and purified by affinity chroma-
tography using Protein A-Sepharose CL-4B 
(Amersham, Sweden). The IgG fractions were pulled 
together and dialyzed against PBS. The aliquots of 
purified antibodies were stored at – 70 °C.
Collection of polyclonal serum
The polyclonal serum has been collected from an 
immunized mouse by tail bleed before the hybrido-
mas production was performed. The collected blood 
was incubated at 37 °C for 1 h then transferred to 
4 °C for 2 hrs, and after that spun down at 1500 rpm 
for 15 min at 4 °C. Serum was removed from cell 
pellet, diluted with equal volume of glycerol and 
stored at – 20 °C. 
Cell lines
U373 (human glioblastoma), HEK293 (human 
embryonic kidney), MCF-7 (human breast adeno-
carcinoma), A549 (human lung carcinoma epitheli-
al cells), HEPG2 (human liver carcinoma cell line), 
HeLa (human cervical cancer cells), Jurkat (human 
acute T cell leukemia) and Primary human fibro-
blasts were grown in DMEM medium supplement-
ed with 10 % (v/v) fetal calf serum (FCS) and 2 mM 
L-glutamine. 
Immunoblotting of cell lysates
U373, HEK293, MCF-7, A549, HEPG2, HeLa, 
Jurkat and Primary human fibroblasts were lysed 
with lysis buffer (50 mM Tris-HCI, pH 7.5, 150 mM 
NaCl, 1 % NP 40, 50 mM NaF, 2 mM EDTA, 10 mM 
Na4P2O7) containing the protease inhibitors cocktail 
(Roche Molecular Diagnostics, France) and spun 
down at 10000 rpm for 10 min. Protein concentration 
in supernatant was estimated by BSA assay (Pierce, 
USA), and equal amounts of protein (50 μg) were re-
solved in SDS-PAGE. Gels were transferred to poly-
vinylidene difluoride (PVDF) membrane (Millipore, 
USA). The membrane was blocked with 0.5 % gela-
tine in PBS containing 0.05 % Tween-20 (PBST) for 
1 h at RT and incubated overnight (o/n) with purified 
antibodies of positive clones at 4 °C. After washing 
with PBS-T, membrane was stained with HRP-
conjugated goat anti-mouse lgG (Promega, USA) 
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during 1 h at RT. As a loading control, mouse anti-
actin antibody was used (Sigma, USA). Finaly, mem-
branes were developed by ECL Western blotting re-
agent (Amersham, Sweden). 
Immunoprecipitation
The antibodies obtained from clone D4 (1μg) were 
incubated with 25 μl of 50 % suspension of Protein 
A-Sepharose CL-4B (Amersham, Sweden) for 2 h at 
4 °C. Then, the beads were washed three times in ly-
sis buffer and the lysate (500 μg of protein) from 
HEK 293 cell line was added. After incubation o/n at 
4° C, beads were washed four times with 1 ml of lysis 
buffer. Immune complexes were removed from beads 
by boiling in SDS gel-loading buffer (5X) and sepa-
rated by SDS-PAGE. Resolved proteins were visual-
ized by Coomassie staining or transferred onto PVDF 
membrane for Western blotting. 
Immunofluorescence analysis
MCF-7 cells cultured on glass slides were fixed 
with methanol for 5 min at room temperature. 
Thereafter, the cells were treated with 0.2 % Triton 
X100 in PBS for 15 min. The samples were incubat-
ed for 30 min in 10 mM cupric sulphate in 50 mM 
ammonium acetate, pH 5.0, to eliminate autofluores-
cence. Non-specific binding was blocked after incu-
bation with 10 % FCS for 30 min. Antibodies ob-
tained from clone D4 (anti-Rictor) were used in the 
concentration of 1 μg/ml. The secondary FITC conju-
gated anti-mouse antibodies were applied in dilution 
1:100 (Jackson ImmunoResearch, West Grove, PA, 
USA). As negative control, MCF7 cells were incu-
bated with secondary FITC conjugated anti-mouse 
antibodies alone. Nuclei were counterstained with PI. 
All microscopy studies were performed using Leica 
DM1000 light microscope (Leica, Wetzlar, Germany).
Results and Discussion
Despite the progress toward understanding the 
control mechanism of both anabolic and catabolic 
processes by mTOR via mTORC1, the function and 
regulation of mTORC2 currently are not well un-
derstood. We were interested in elucidating the mo-
lecular mechanisms of functioning of the Rictor 
protein independently and mTORC2 in general as 
well as in studying the localization and colocaliza-
tion of both complexes in cells in different physio-
logical and pathophysiological conditions. In the 
course of this study, we noticed the lack of commer-
cially available highly specific Rictor monoclonal 
antibodies, which would recognize efficiently the 
endogenous Rictor in all immunoassays (Western-
blot, Immunoprecipitation and Immunofluorescence). 
Therefore we decided to develop the monoclonal an-
tibodies that meet all mentioned requirements.
Therefore, at the first stage, we used the bacterial 
expression system to produce the recombinant 
N-terminal peptide of human Rictor for the mouse 
immunization and hybridoma screening. GST-
NtRictor was highly expressed upon the IPTG in-
duction and shown to be soluble under the native 
conditions. For the GST-NtRictor fusion protein pu-
rification, the Glutathione-Sepharose affinity chro-
matography was used (Fig. 1). 
At the second stage, we maintained the standard 
scheme of immunization, boosting animals every 
2 weeks. The titer of anti-Rictor antibodies in the se-
rum of immunized mice was nearly 10−5 after the 
third immunization. The immune spleen cells were 
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Fig. 1. Affinity purification of recombinant GST-NtRictor and 
analysis by SDS-PAGE. Affinity purification of GST-NtRictor 
protein on GST-sepharose under native conditions. The GST-
NtRictor expressing cells were incubated with the GST-sepha-
rose as described in Material and Methods. After elution [the] 
obtained fractions were resolved by SDS-PAGE and Coomassie 
stained. The position of recombinant GST-NtRictor is indicated 
by arrowv
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fused with the myeloma cells Sp2/0 using PEG. The 
resulting hybridoma cells were selected in HAT me-
dium and tested for the production of the anti-Rictor 
antibodies in ELISA. GST protein was used as a 
negative control. We selected 60 hybridoma clones 
positive for GST-NtRictor but not for the GST pro-
tein in the first round of screening. For the clones 
selected the second ELISA screening was performed 
three days later that confirmed the GST-NtRictor 
specificity for 11 clones. 
Then the supernatants from 11 positive clones 
were further tested by Western blotting using GST-
NtRictor fusion protein. In this analysis, we con-
firmed the Rictor recognition by eleven clones 
(Fig. 2). Six positive clones, which showed the high-
est immune reactivity (E5/6, G2/6, B4/6, D4/2, D4/7 
and C7/5) were subcloned twice using limiting dilu-
tion method. Subcloned hybridomas were tested by 
ELISA and Western blotting and showed specific 
recognition of recombinant GST-NtRictor. The ob-
tained results clearly indicated that only one mAB, 
which designated as D4, recognized a protein at the 
level corresponding to GST-NtRictor in Western blot 
analysis using GST-NtRictor as antigen (data not 
shown).
Next, to determine whether the selected D4 mAb 
can recognize the endogenous Rictor, we tested their 
specificity in Western blotting on the one hand using 
cell lysates from different cell lines and in immuno-
precipitation assay using a total lysate of the HEK 
293 cell line on the other hand. We found that in 
Western-blot D4 mAb recognizes a protein of ap-
proximately 190 kDa in all cell lines (Fig. 3). The 
molecular weight of an immnoreactive band corre-
sponds to the canonical isoform of Rictor. Taking 
into account that as an antigen for the immunization 
and hybridoma screening we used human Rictor 
peptide, at the next stage we analyzed the cross reac-
tivity of the generated D4 mAb with Rictor from 
other mammals. Western blot analysis of cell lysates 
from the cell lines of different origin showed the 
cross-reactivity of mAb produced by D4 clone with 
Rictor from mouse, rat, and human (data not shown). 
Furthermore, Fig. 4 shows the ability of selected 
mAb to immunoprecipitate specifically Rictor from 
HEK 293 cells.
Finally, we examined D4 mAb in immunofluores-
cence assay using MCF7 cell line. The analysis was 
performed as described in Materials and methods. 
As shown in Fig 5, D4 mAb revealed mostly a dif-
fuse, cytoplasmic distribution of the endogenous 
Rictor and minor nuclear localization (Fig. 5). As a 
negative control, the MCF7 cells were incubated 
with the secondary FITC conjugated anti-mouse an-
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Fig. 2. Western-blot analysis of hybridoma supernatants from 
different clones with recombinant GST-NtRictor. 
Recombinant GST-NtRictor was separated in numerous lanes by 
SDS-PAGE and transferred to PVDF membrane. The strips of 
membranes, corresponding to one lane were immunoblotted 
with hybridoma media from Rictor positive supernatants. Anti-
Rictor polyclonal serum and 10% FBS in cell culture media 
were used as positive and negative control, respectively.
The position of GST-NtRictor protein is indicated by arrow
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Fig. 3. Western-blot analysis of monoclonal antibody D4 using 
panel of cell lines.
Endogenous Rictor is specifically recognized by D4 mAb in 
Western blotting of panel of mammalian cell lines. Total cell 
lysates were separated by SDS-PAGE and immunoblotted with 
D4 mAb. HEK293 cell line transiently transfected with pRK5/
Myc-Rictor plasmid was used as positive control.
The position of Rictor is indicated by arrow
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tibodies alone (data not shown). There are long-
standing speculations about subcellular localization 
of mTORC2 and Rictor as a part of complex. 
According to the most important reports that investi-
gate the TORC2 and mTORC2 localization using 
confocal imaging and not only (subcellular fraction-
ation and immuno-EM), mTORC2 has consistently 
been identified in proximity to mitochondria, the ER 
(endoplasmic reticulum) and MAM (mitochondria-
associated ER membranes) [16–19]. Other studies 
suggest that mTORC2 is in the nucleus (a nuclear 
function for mTORC2 is so far unknown) or at the 
plasma membrane (suggests that only a minor frac-
tion of mTORC2 is at the plasma membrane) [20–
28]. Taking together, the subcellular localization of 
Rictor, detected with D4 mAb, correlates with the 
previously published immunofluorescence analysis 
data [16–28].
In summary, this study describes the production 
of monoclonal antibody using hybridoma technique, 
which specifically recognizes mammalian protein 
Rictor. The generated mAb could be suitable for va-
rious immunoassays, including ELISA, Western 
blotting, immunoprecipitation and immunofluores-
cence assays. Application of the presented new anti-
bodies especially in confocal microscopy may be 
helpful in testing the co-localization of the investi-
gated antigen with other proteins. Furthermore, this 
mAb could be a useful tool in study of both Rictor- 
and mTORC2-mediated signalling under the normal 
and different pathophysiological conditions. 
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Отримання моноклональних антитіл до компонента 
комплекса mTORC2 білка Rictor 
О. М. Маланчук 
Ціль. Rictor є унікальним компонентом білкового комплекса 
mTORC2, що активується ростовими факторами та регулює 
ріст клітин, виживання та міграцію. В даній статті описано 
процедуру отримання моноклональних антитіл, специфічних 
до Rictor, а також особливості їх використання у різноманітних 
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імунологічних методах аналізу. Методи. Для отримання моно-
клональних антитіл було використано гібридомну технологію. 
Імунізацію проводили рекомбінантним GST-таг злитим 
N-термінальним фрагментом Rictor, синтезованим в E. coli. 
Результати. Отримано специфічні моноклональні антитіла 
проти Rictor. Висновки. Отримані моноклональні антитіла 
специфічно розпізнають рекомбінантний та ендогенний Rictor 
в Вестерн-блот аналізі, імунопреципітації та імунофлюорис-
ценції клітин ссавців, та можуть бути використані як необхід-
ний інстумент досліджень при вивченні як індивідуальної фізі-
ологічної ролі Rictor в клітині, так і в складі комплекса 
mTORC2 в цілому.
К л юч ов і  с л ов а: Rictor, mTORC2, гібридомна технологія, 
моноклональні антитіла.
Получение моноклональных антител к компоненту 
комплекса mTORC2 белку Rictor 
О. Н. Маланчук
Цель. Rictor является уникальным компонентом белкового 
комплекса mTORC2, который активируется ростовыми факто-
рами и регулирует рост клеток, выживание и миграцию. В дан-
ной статье описано процедуру получения моноклональных 
антител, специфичных к Rictor, а также особенности их ис-
пользования в различных иммунологических методах анализа. 
Методы. Для получения моноклональных антител была ис-
пользована гибридомная технология. Иммунизацию проводи-
ли рекомбинантным GST-таг слитым N-терминальным фраг-
ментом Rictor, синтезированном в E.coli. Результаты. Полу-
чены специфические моноклональные антитела против Rictor. 
Выводы. Полученные моноклональные антитела специфично 
распознают рекомбинантный и эндогенный Rictor в Вестерн-
блот анализе, иммунопреципитации и иммунофлюорисценции 
клеток млекопитающих, и могут быть использованы как необ-
ходимый инстумент исследований при изучении как индиви-
дуальной физиологической роли Rictor а в клетке, так и в со-
ставе комплекса mTORC2 в целом.
К л юч е в ы е  с л ов а: Rictor, mTORC2, гибридомная техно-
логия, моноклональные антитела.
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